What changed from existing technology?
This study found that higher levels of a protein called S100A8/A9 in the blood may increase the risk of brain metastasis in patients with a rare and aggressive type of breast cancer called inflammatory breast cancer.
This is the first study to specifically investigate the association between serum S100A8/A9 levels and brain metastasis risk in inflammatory breast cancer patients.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
associated with increased risk of brain metastasis in patients with inflammatory breast cancer. Inflammatory breast cancer (IBC) is a rare but highly aggress
Title ↗e in aggressive breast cancers, but their role in IBC remains undefined. This study evaluated whether serum S100A8/A9 levels are associated with clinical
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding may help identify patients with inflammatory breast cancer who are at higher risk of brain metastasis, potentially guiding more personalized treatment strategies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.